Learn more Multiple insiders secured a larger position in MBX Biosciences, Inc. (NASDAQ:MBX) shares over the last 12 months. This is reassuring as this suggests that insiders have increased optimism ...
MBX Biosciences has rallied more than 230% over the past year, but there's room for still more upside from current levels, according to UBS.
Further signs that the biotech initial public offering (IPO) market is picking up have come with a filing by MBX Biosciences, seeking around $100 million to take a hypoparathyroidism candidate into ...
"Mark is an exceptional commercial leader with a demonstrated ability to build and scale commercial organizations and bring ...
MBX Biosciences (NASDAQ:MBX) used its Obesity Day event to outline preliminary clinical data for its lead obesity candidate ...
The average one-year price target for MBX Biosciences (NasdaqGS:MBX) has been revised to $69.55 / share. This is an increase ...
CARMEL, Ind., April 07, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide ...
Preliminary blinded data from ongoing Phase 1 trial demonstrated mean weight loss of 7% (range 0-16%) at 8 weeks in first MAD Part B cohort (n=8, ...
Results from Phase 2 trial of once-weekly canvuparatide accepted for oral presentation at ENDO in June 2026 Phase 3 trial of ...
The president & CEO of MBX Biosciences reported the acquisition of 18,500 indirectly held shares for about $526,000 on March 13, 2026. The indirect holdings (486,777 shares) are maintained via the P.
MBX Biosciences MBX, a clinical-stage biotech focused on developing treatments for endocrine and metabolic disorders, set terms for its initial public offering on Monday, with plans to offer 8.5 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results